Published in Cardiovascular Week, September 22nd, 2008
In this Phase II trial, CVBT's drug candidate containing human Fibroblast Growth Factor-1 (FGF-1), will be injected into patients' hearts, stimulating a healing process called angiogenesis. The drug will be delivered using the NOGA(R) XP Cardiac...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.